Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]

Ferrufino CP, Munakata J, Wei W, et al. Clinicoecon Outcomes Res. 2018;10: 805—819. On page 810, Table 4, Drug costs column, Methotrexate, the Unit WAC was listed as $1 however it should have been $2.36. On page 817, Table S2, the monitoring costs for (A) csDMARD-IR and (B) TNF-IR...

Full description

Saved in:
Bibliographic Details
Main Authors: Ferrufino CP (Author), Munakata J (Author), Wei W (Author), Proudfoot C (Author), Kuznik A (Author), Boklage SH (Author), Chen C (Author)
Format: Book
Published: Dove Medical Press, 2019-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available